Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Brenner Tumor 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 19Docetaxel 17Cetuximab 12Carboplatin 12Radiotherapy 11Magnetic Resonance Spectroscopy 10Biopsy 10pembrolizumab 9Paclitaxel 9Radiotherapy, Intensity-Modulated 8Immunohistochemistry 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Chemotherapy, Adjuvant 7Specimen Handling 6Radiotherapy, Conformal 5Radiosurgery 5Gene Expression Profiling 5Fluorodeoxyglucose F18 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Polymerase Chain Reaction 4Nivolumab 4Bevacizumab 4trastuzumab deruxtecan 3sargramostim 3bicalutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × VTX-2337 × Clear all
NCT01334177 2015-03-05

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

University of Washington

Phase 1 Completed
13 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡